These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34315812)

  • 1. Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.
    Lucey M; Ashik T; Marzook A; Wang Y; Goulding J; Oishi A; Broichhagen J; Hodson DJ; Minnion J; Elani Y; Jockers R; Briddon SJ; Bloom SR; Tomas A; Jones B
    Mol Pharmacol; 2021 Oct; 100(4):319-334. PubMed ID: 34315812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists.
    Lucey M; Pickford P; Bitsi S; Minnion J; Ungewiss J; Schoeneberg K; Rutter GA; Bloom SR; Tomas A; Jones B
    Mol Metab; 2020 Jul; 37():100991. PubMed ID: 32278079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
    Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
    J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1.
    Marzook A; Chen S; Pickford P; Lucey M; Wang Y; Corrêa IR; Broichhagen J; Hodson DJ; Salem V; Rutter GA; Tan TM; Bloom SR; Tomas A; Jones B
    Biochem Pharmacol; 2021 Aug; 190():114656. PubMed ID: 34129856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced incretin receptor trafficking upon activation enhances glycemic control and reverses obesity in diet-induced obese mice.
    Bauri R; Bele S; Edelli J; Reddy NC; Kurukuti S; Devasia T; Ibrahim A; Rai V; Mitra P
    Am J Physiol Cell Physiol; 2024 Jul; 327(1):C74-C96. PubMed ID: 38738303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells.
    Fang Z; Chen S; Manchanda Y; Bitsi S; Pickford P; David A; Shchepinova MM; Corrêa IR; Hodson DJ; Broichhagen J; Tate EW; Reimann F; Salem V; Rutter GA; Tan T; Bloom SR; Tomas A; Jones B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33182425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists.
    Fletcher MM; Halls ML; Zhao P; Clydesdale L; Christopoulos A; Sexton PM; Wootten D
    Biochem Pharmacol; 2018 Oct; 156():406-419. PubMed ID: 30195733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
    Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
    Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic β-Cells.
    Buenaventura T; Kanda N; Douzenis PC; Jones B; Bloom SR; Chabosseau P; Corrêa IR; Bosco D; Piemonti L; Marchetti P; Johnson PR; Shapiro AMJ; Rutter GA; Tomas A
    Diabetes; 2018 Mar; 67(3):385-399. PubMed ID: 29284659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
    Brown JD; McAnally D; Ayala JE; Burmeister MA; Morfa C; Smith L; Ayala JE
    Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R595-R608. PubMed ID: 29949410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting GLP-1 receptor trafficking to improve agonist efficacy.
    Jones B; Buenaventura T; Kanda N; Chabosseau P; Owen BM; Scott R; Goldin R; Angkathunyakul N; Corrêa IR; Bosco D; Johnson PR; Piemonti L; Marchetti P; Shapiro AMJ; Cochran BJ; Hanyaloglu AC; Inoue A; Tan T; Rutter GA; Tomas A; Bloom SR
    Nat Commun; 2018 Apr; 9(1):1602. PubMed ID: 29686402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time trafficking and signaling of the glucagon-like peptide-1 receptor.
    Roed SN; Wismann P; Underwood CR; Kulahin N; Iversen H; Cappelen KA; Schäffer L; Lehtonen J; Hecksher-Soerensen J; Secher A; Mathiesen JM; Bräuner-Osborne H; Whistler JL; Knudsen SM; Waldhoer M
    Mol Cell Endocrinol; 2014 Feb; 382(2):938-49. PubMed ID: 24275181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling.
    Lei S; Meng Q; Liu Y; Liu Q; Dai A; Cai X; Wang MW; Zhou Q; Zhou H; Yang D
    Eur J Pharmacol; 2024 Apr; 968():176419. PubMed ID: 38360293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biased agonists with less glucagon-like peptide-1 receptor-mediated endocytosis prolong hypoglycaemic effects.
    Wu Q; Chen S; Zhu H; Xu N; Yang Q; Yao W; Gao X
    Eur J Pharmacol; 2021 Sep; 907():174203. PubMed ID: 34048741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.
    Lamont BJ; Li Y; Kwan E; Brown TJ; Gaisano H; Drucker DJ
    J Clin Invest; 2012 Jan; 122(1):388-402. PubMed ID: 22182839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1.
    Hager MV; Clydesdale L; Gellman SH; Sexton PM; Wootten D
    Biochem Pharmacol; 2017 Jul; 136():99-108. PubMed ID: 28363772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.
    Roed SN; Nøhr AC; Wismann P; Iversen H; Bräuner-Osborne H; Knudsen SM; Waldhoer M
    J Biol Chem; 2015 Jan; 290(2):1233-43. PubMed ID: 25451942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
    Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
    Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles.
    Bueno AB; Showalter AD; Wainscott DB; Stutsman C; Marín A; Ficorilli J; Cabrera O; Willard FS; Sloop KW
    J Biol Chem; 2016 May; 291(20):10700-15. PubMed ID: 26975372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
    Kawai T; Sun B; Yoshino H; Feng D; Suzuki Y; Fukazawa M; Nagao S; Wainscott DB; Showalter AD; Droz BA; Kobilka TS; Coghlan MP; Willard FS; Kawabe Y; Kobilka BK; Sloop KW
    Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29959-29967. PubMed ID: 33177239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.